Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Show more
Location: One Main Street, Cambridge, MA, 02142, United States | Website: https://cullinantherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
491.6M
52 Wk Range
$6.85 - $20.96
Previous Close
$8.33
Open
$8.28
Volume
77,286
Day Range
$8.09 - $8.33
Enterprise Value
189.6M
Cash
303.8M
Avg Qtr Burn
-37.55M
Insider Ownership
4.55%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zipalertinib Details Non-small cell lung carcinoma | Phase 3 Update | |
Zipalertinib Details NSCLC with uncommon non–ex20ins EGFR mutations | Phase 2 Data readout | |
Zipalertinib Details Non-small cell lung carcinoma | Phase 1/2 Data readout | |
CLN-619 (MICA/B) +/- pembrolizumab Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CLN-617 (IL-2 and IL-12) +/- pembrolizumab Details Cancer, Solid tumor/s | Phase 1 Update | |
CLN-049 (FLT3xCD3) Details Relapsed/refractory acute myeloid leukemia, Acute myeloid leukemia | Phase 1 Update | |
CLN-978 (CD19xCD3) Details Non-Hodgkin lymphoma, Blood cancer, Cancer | Phase 1 Update | |
CLN-619 (MICA/B) Details Multiple myeloma | Phase 1 Initiation | |
CLN-978 (CD19xCD3) Details Rheumatoid Arthritis | Phase 1 Initiation | |
CLN-978 (CD19xCD3) Details Sjögren’s disease (SjD) | Phase 1 Initiation | |
CLN-978 (CD19xCD3) Details Autoimmune disease, Systemic lupus erythematosus | Phase 1 Initiation | |
CLN-418 (B7H4x4-1BB) Details Solid tumor/s | Failed Discontinued |